SAB Biotherapeutics Inc. is a cutting-edge biotechnology company focused on developing and commercializing innovative immunotherapies for a range of diseases. With its proprietary platform technology, SAB is able to rapidly produce fully human polyclonal antibodies, providing a highly scalable and cost-effective approach to treating conditions such as cancer, infectious diseases, and autoimmune disorders.
